PRRT2 and cancer: Nuclear PKCθ-positive phenotype, together with cell surface vimentin-positive and ABCB5-positive phenotypes, a CSC-like marker associated with therapeutic resistance, is found in a higher proportion in brain metastases of patients with breast cancer than in primary breast tumors, indicating an association between PKCθ and cancer metastasis [123].